Pharmacokinetic evaluation of topical calcineurin inhibitors for treatment of allergic conjunctivitis

Bibliography

• Kari O, Saari KM. Updates in the treatment of ocular allergies. J Asthma Allergy 2010;3:149-58
   Google Scholar
• Sy H, Bielory L. Atopic keratoconjunctivitis. Allergy Asthma Proc 2013;34(1):33-41
   PubMed Web of Science ®Google Scholar
• Bielory L. Ocular allergy treatment. Immunol Allergy Clin North Am 2008;28:189-224; vii
   PubMed Web of Science ®Google Scholar
• De Smedt S, Nkhurikiye J, Fonteyne Y, et al. Vernal keratoconjunctivitis in school children in Rwanda and its association with socio-economic status: a population-based survey. Am J Trop Med Hyg 2011;85:711-17
   PubMed Web of Science ®Google Scholar
• De Smedt S, Wildner G, Kestelyn P. Vernal keratoconjunctivitis: an update. Br J Ophthalmol 2013;97(1):9-14
   PubMed Web of Science ®Google Scholar
• La Rosa M, Lionetti E, Reibaldi M, et al. Allergic conjunctivitis: a comprehensive review of the literature. Ital J Pediatr 2013;39:18
   PubMed Web of Science ®Google Scholar
• McCaffrey PG, Perrino BA, Soderline TR, et al. NF-ATp, a T lymphocyte DNA-binding protein that is a target for calcineurin and immunosuppressive drugs. J Biol Chem 1993;268(5):3747-52
   PubMed Web of Science ®Google Scholar
• Hunter PA, Wilhelmus KR, Rice NS, et al. Cyclosporin a applied topically to the recipient eye inhibits corneal graft rejection. Clin Exp Immunol 1981;45(1):173-7
   PubMed Web of Science ®Google Scholar
• Whitcup SM, Chan CC, Luyo DA, et al. Topical cyclosporine inhibits mast cell-mediated conjunctivitis. Invest Ophthalmol Vis Sci 1996;37(13):2686-93
   PubMed Web of Science ®Google Scholar
• Ebihara N, Ohashi Y, Uchio E, et al. A large prospective observational study of novel cyclosporine 0.1% aqueous ophthalmic solution in the treatment of severe allergic conjunctivitis. J Ocul Pharmacol Ther 2009;25(4):365-72
   PubMed Web of Science ®Google Scholar
• DePaulis A, Cirillo R, Ciccarelli A, et al. FK-506, a potent novel inhibitor of the release of proinflammatory mediators from human Fc epsilon RI+ cells. J Immunol 1991;146(7):2374-81
   PubMed Web of Science ®Google Scholar
• Protopic® (Tacrolimus) ointment 0.03 % and ointment 0.1 % (US prescribing information). Astellas Pharma US, Inc; Deerfield (IL); 2011
   Google Scholar
• Elidel® (Pimecrolimus) cream 1 % (US prescribing information). Novartis Pharmaceuticals Corporation; East Hanover (NJ); 2001
   Google Scholar
• Ashcroft DM, Chen LC, Garside R, et al. Topical pimecrolimus for eczema. Cochrane Database Syst Rev 2007;(4):CD005500
   Google Scholar
• Gutfreund K, Bienias W, Sczewczyk A, et al. Topical calcineurin inhibitors in dermatology. Part I: properties, methods, and effectiveness of drug use. Postepy Dermatol Alergol 2013;30(3):165-9
   PubMed Web of Science ®Google Scholar
• Kempen JH, Gangaputra S, Daniel E, et al. Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: acritical assessment of the evidence. Am J Ophthalmol 2008;146(6):802-12
   PubMed Web of Science ®Google Scholar
• Lallemand F, Felt-Baeyens O, Besseghir K, et al. Cyclosporine A delivery to the eye: a pharmaceutical challenge. Eur J Pharm Biopharm 2003;56(3):307-18
   PubMed Web of Science ®Google Scholar
• Acheampong AA, Shackleton M, Tang-Liu DD, et al. Distribution of cyclosporin A in ocular tissues after topical administration to albino rabbits and beagle dogs. Curr Eye Res 1999;18(2):91-103
   PubMed Web of Science ®Google Scholar
• Small DS, Acheampong A, Reis B, et al. Blood concentrations of cyclosporin A during long-term treatment with cyclosporin a ophthalmic emulsions inpatients with moderate to severe dry eye disease. J Ocul Pharmacol Ther 2002;18(5):411-18
   PubMed Web of Science ®Google Scholar
• Sall K, Stevenson OD, Mudorf TK, et al. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA phase 3 study group. Ophthalmology 2000;107(4):631-9
   PubMed Web of Science ®Google Scholar
• Barber LD, Pflugfelder SC, Tauber J, et al. Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years. Ophthalmology 2005;112(10):1790-4
   PubMed Web of Science ®Google Scholar
• Pleyer U, Lutz S, Jusko WJ, et al. Ocular absorption of topically applied FK506 from liposomal and oil formulations in the rabbit eye. Invest Ophthalmol Vis Sci 1993;34:2737-42
   PubMed Web of Science ®Google Scholar
• Bertelmann E, Pleyer U. Immunomodulatory therapy in ophthalmology – is there a place for topical application? Ophthalmologica 2004;218:359-67
   PubMed Web of Science ®Google Scholar
• Benelli U, Lepri A, Del Tacca M, et al. FK-506 delays corneal graft rejection in a model of corneal xenotransplantation. J Ocul Pharmacol Ther 1996;12:425-31
   PubMed Web of Science ®Google Scholar
• Ruzicka T, Bieber T, Schopf E, et al. A short-term trial of tacrolimus ointment for atopic dermatitis. European tacrolimus multicenter atopic dermatitis study group. N Engl J Med 1997;337:816-21
   PubMed Web of Science ®Google Scholar
• Boguniewicz M, Fiedler VC, Raimer S, et al. A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. Pediatric Tacrolimus Study Group. J Allergy Clin Immunol 1998;102:637-44
   PubMed Web of Science ®Google Scholar
• Schneider L, Tilles S, Lio P, et al. Atopic dermatitis: a practice parameter update 2012. J Allergy Clin Immunol 2013;131(2):295-9
   PubMed Web of Science ®Google Scholar
• Yuan J, Zhai JJ, Chen JQ, et al. Preparation of 0.05% FK506 suspension eyedrops and its pharmacokinetics after topical ocular administration. J Ocul Pharmacol Ther 2009;25(4):345-50
   PubMed Web of Science ®Google Scholar
• Attas-Fox L, Barkana Y, Iskhakov V, et al. Topical tacrolimus 0.03% ointment for intractable allergic conjunctivitis: an open-label pilot study. Curr Eye Res 2008;33(7):545-9
   PubMed Web of Science ®Google Scholar
• Nell B, Walde J, Billich A, et al. The effect of topical pimecrolimus on keratoconjunctivitis sicca and chronic superficial keratitis in dogs: results from an exploratory study. Vet Ophthalmol 2005;8(1):39-46
   PubMed Web of Science ®Google Scholar
• Ofri R, Lambrou GN, Allgoewer I, et al. Clinical evaluation of pimecrolimus eye drops for treatment of canine keratoconjunctivitis sicca: a comparison with cyclosporine A. Vet J 2009;179(1):70-7
   PubMed Web of Science ®Google Scholar
• Tang-Liu DD, Acheampong A. Ocular pharmacokinetics and safety of ciclosporin, a novel topical treatment for dry eye. Clin Pharmacokinet 2005;44(3):247-61
   PubMed Web of Science ®Google Scholar
• Ohashi Y, Ebihara N, Fujishima H, et al. A randomized, placebo-controlled clinical trial of tacrolimus ophthalmic suspension 0.1% in severe allergic conjunctivitis. J Ocul Pharmacol Ther 2010;26(2):165-74
   PubMed Web of Science ®Google Scholar
• Sanz-Marco E, Udaondo P, García-Delpech S, et al. Treatment of refractory dry eye associated with graft versus host disease with 0.03% tacrolimus eyedrops. J Ocul Pharmacol Ther 2013;29(8):776-83
   PubMed Web of Science ®Google Scholar
• Akpek EK, Dart JK, Watson S, et al. A randomized trial of topical cyclosporin 0.05% in topical steroid-resistant atopic keratoconjunctivitis. Ophthalmology 2004;111:476-82
   PubMed Web of Science ®Google Scholar
• Daniell M, Constantinou M, Vu HT, et al. Randomised controlled trial of topical ciclosporin A in steroid dependent allergic conjunctivitis. Br J Ophthalmol 2006;90(4):461-4
   PubMed Web of Science ®Google Scholar
• Wan KH, Chen LJ, Rong SS, et al. Topical cyclosporine in the treatment of allergic conjunctivitis: a meta-analysis. Ophthalmology 2013, doi:pii: S0161-6420(13)00329-1. 10.1016/j.ophtha.2013.03.044
   Web of Science ®Google Scholar
• Ozcan AA, Ersoz TR, Dulger E. Management of severe allergic conjunctivitis with topical cyclosporin A 0.05% eyedrops. Cornea 2007;26(9):1035-8
   PubMed Web of Science ®Google Scholar
• Spadavecchia L, Fanelli P, Tesse R, et al. Efficacy of 1.25% and 1% topical cyclosporine in the treatment of severe vernal keratoconjunctivitis in childhood. Pediatr Allergy Immunol 2006;17(7):527-32
   PubMed Web of Science ®Google Scholar
• Hingorani M, Moodaley L, Calder VL, et al. A randomized, placebo-controlled trial of topical cyclosporin A in steroid-dependent atopic keratoconjunctivitis. Ophthalmology 1998;105(9):1715-20
   PubMed Web of Science ®Google Scholar
• Vichyanond P, Tantimongkolsuk C, Dumrongkigchaiporn P, et al. Vernal keratoconjunctivitis: result of a novel therapy with 0.1% topical ophthalmic FK-506 ointment. J Allergy Clin Immunol 2004;113(2):355-8
   PubMed Web of Science ®Google Scholar
• Kheirkhah A, Zavareh MK, Farzbod F, et al. Topical 0.005% tacrolimus eye drop for refractory vernal keratoconjunctivitis. Eye (Lond) 2011;25:872-80
   PubMed Web of Science ®Google Scholar
• Rikkers SM, Holland GN, Drayton GE, et al. Topical tacrolimus treatment of atopic eyelid disease. Am J Ophthalmol 2003;135(3):297-302
   PubMed Web of Science ®Google Scholar
• Virtanen HM, Reitamo S, Kari M, Kari O. Effect of 0.03% tacrolimus ointment on conjunctival cytology in patients with severe atopic blepharoconjunctivitis: a retrospective study. Acta Ophthalmol Scand 2006;84(5):693-5
   PubMedGoogle Scholar
• Kymionis GD, Goldman D, Ide T, Yoo SH. Tacrolimus ointment 0.03% in the eye for treatment of giant papillary conjunctivitis. Cornea 2008;27(2):228-9
   PubMed Web of Science ®Google Scholar
• Ohashi Y, Ebihara N, Fujishima H, et al. A randomized, placebo-controlled clinical trial of tacrolimus ophthalmic suspension 0.1 % in severe allergic conjunctivitis. J Ocul Pharmacol Ther 2010;26:165-74
   PubMed Web of Science ®Google Scholar
• Labcharoenwongs P, Jirapongsananuruk O, Visitsunthorn N, et al. A double-masked comparison of 0.1% tacrolimus ointment and 2% cyclosporine eye drops in the treatment of vernal keratoconjunctivitis in children. Asian Pac J Allergy Immunol 2012;30:177-84
   PubMed Web of Science ®Google Scholar
• Ofri R, Lambrou GN, Allgoewer I, et al. Clinical evaluation of pimecrolimus eye drops for treatment of canine keratoconjunctivitis sicca: a comparison with cyclosporine A. Vet J 2009;179(1):70-7
   PubMed Web of Science ®Google Scholar